U.S. Regulatory Climate Attracts Nearly Half Of Israeli Startups For Incorporation

by THEFUTURE.TEAM

September 13, 2025

Overview Of A Shifting Landscape

The Israel Advanced Technology Industries Association (IATI) has revealed a striking trend: nearly 45 percent of startups in 2025 are incorporating outside Israel. This marks a significant departure from 2022, when approximately 80 percent of new companies registered domestically. The shift is largely attributed to the relatively easier regulatory environment in the United States, with Delaware emerging as a preferred hub.

Government Policy And Economic Ripple Effects

The tide began to turn in 2023 when an anticipated overhaul of Israel’s judicial system prompted many startups to look abroad. Although the controversial reforms were set aside following the October 7, 2023 attacks and the subsequent conflict, the momentum for U.S. incorporation has persisted. Industry leaders have raised alarms about these trends, warning that the relocation of economic activity abroad could undermine the strong global reputation of Israel’s high-tech sector, which is a critical driver of national economic performance.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Industry Voices And Strategic Concerns

Dan Shamgar, chair of the IATI’s lawyers and accountants committee and partner at the Meitar law firm, emphasized, “Incorporation abroad gradually shifts economic activity out of Israel and erodes the brand of Israeli high-tech.” Shamgar highlighted that while U.S. policies in the past year have actively encouraged companies to register and operate domestically, economic policymakers in Israel have yet to implement comparable incentives. The absence of robust governmental support raises questions about maintaining the nation’s competitive edge in high technology, which encompasses roughly 20 percent of the country’s economic activity, 15 percent of its jobs, and more than half of its exports.

Challenges And The Road Ahead

Further concerns at the IATI conference include the sector’s reliance on foreign capital, with domestic investment lagging behind, and the critical need for renewed focus on health technology—a market segment that has recently experienced a downturn. These issues underscore the imperative for state intervention to ensure that Israeli high-tech companies continue to thrive on home soil.

Conclusion

The current trend of startups incorporating in the United States is symptomatic of broader regulatory and economic challenges facing the Israeli high-tech industry. As global competition intensifies, the call for policy reforms and strategic incentives in Israel becomes ever more urgent. How the government responds in the coming months will be pivotal for preserving the nation’s high-tech legacy and securing the future of its economic ecosystem.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news